Schizophrenia Clinical Trial
Official title:
Switching From Risperidone Long Acting Injection (Consta®) to Paliperidone Palmitate (Sustenna®) in Patients With Schizophrenia and Its Influence on Subjective Well-Being: A Prospective Observational Study
The aim of this study is observation of effectiveness and side effect of patients with schizophrenia who will switch the antipsychotics from risperidone long acting injection to paliperidone palmitate.
Status | Completed |
Enrollment | 50 |
Est. completion date | May 2015 |
Est. primary completion date | May 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Age: 18 ~ 65 - Patient with schizophrenia according to DSM-IV criteria - Patient have signed on the informed consent, and well understood the objective and procedure of this study. - Maintenance therapy more than 6 months with Risperidone Long Acting Injection monotherapy or other with concomitant antipsychotics, and stable dose of Risperidone Long Acting Injection was maintained 8 weeks more. The stable dose of other antipsychotics has been maintained 8 months and more. - Patient wants to switch antipsychotics to Paliperidone Palmitate. - PANSS total score = 80 - Each score of conceptual disorganization(P2), hallucinatory behavior(P3), Suspiciousness/persecution(P6), unusual thought content(G9)in PANSS = 4 - Competent patient who is manage to answer the questionnaires. - In case of female at child-bearing age, consent to use appropriate contraceptive methods(oral pill, contraceptive injection, intrauterine device, double barrier method and contraceptive patch) during entire duration of this study. Exclusion Criteria: - No history of antipsychotics use. - Past history of NMS. - Allergy or hypersensitivity to Risperidone or Paliperidone ER. - Concomitant antipsychotics was oral Risperidone or Paliperidone ER. - Initiating or dose-changing of SSRI, MAOI, TCA within 2 months(maintenance is allowed if those have been stable for at least 30days prior to study entry and would not be any dose changes during the study) - Initiating of Lithium, Valproic acid, Carbamazepine, Topiramate, Lamotrigine or other mood stabilizer within 2months (maintenance is allowed). - Patient who is supposed to be impossible to participate to this study due to clinical risk of suicide or aggressive behavior based on clinician's opinion. - Current substance dependence(DSM-IV) or past history of dependence (more than 6months) - Significant biochemical or hematological abnormality or abnormal finding of urinalysis, based on clinician's opinion. - History of cardiac disease which predispose to QT prolongation(sick sinus, complete AV block, CHF, ventricular tachycardia, hypokalemia or hypocalcemia) or current medication of QT prolonging drugs - Pregnant or breast-feeding female patient. - History of participating to other investigational drug trial within 1month prior to screening. - Investigator or employee at clinical trial center, personnel related to investigator or trial center on this or other study, or family of employee or investigator |
Observational Model: Case-Only, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Seoul National University Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Seoul National University Hospital |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Subjective Well-being Under Neuroleptic Treatment (SWN) | Change from Baseline in SWN score at 108 weeks | No | |
Secondary | Korean Drug Attitude Inventory-10 | Change from Baseline in score at 108 weeks | No | |
Secondary | Positive and Negative Syndrome Scale | 0,4,8,16,24,36,48,60,72,84,96,108 week | No | |
Secondary | Clinical Global Impression-Severity, Improvement | 0,4,8,16,24,36,48,60,72,84,96,108 week | No | |
Secondary | Personal and Social Performance Scale | 0,4,8,16,24,36,48,60,72,84,96,108 week | No | |
Secondary | Symptom Check List-90-Revised | 0,4,8,16,24,36,48,60,72,84,96,108 week | No | |
Secondary | Drug-Induced ExtraPyramidal Symptoms Scale | 0,4,8,16,24,36,48,60,72,84,96,108 week | Yes | |
Secondary | Liverpool University Neuroleptic Side Effect Rating Scale | 0,4,8,16,24,36,48,60,72,84,96,108 week | Yes | |
Secondary | Visual Analog Scale | injection site pain | 0,4,8,16,24,36,48,60,72,84,96,108 week | Yes |
Secondary | ECG | electrocardiogram | 8, 24, 48, 72, 108 week | Yes |
Secondary | blood pressure | 0,4,8,16,24,48,72,108 week | Yes | |
Secondary | Body weight | 0,4,8,16,24,48,72,108 week | Yes | |
Secondary | waist circumference | 0,4,8,16,24,48,72,108 week | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |